Kinsale Capital Group Inc. Grows Stock Position in Amgen Inc. $AMGN

Kinsale Capital Group Inc. raised its holdings in Amgen Inc. (NASDAQ:AMGN) by 4.6% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 35,762 shares of the medical research company’s stock after buying an additional 1,569 shares during the quarter. Amgen comprises 1.9% of Kinsale Capital Group Inc.’s holdings, making the stock its 16th largest position. Kinsale Capital Group Inc.’s holdings in Amgen were worth $11,705,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its stake in Amgen by 1.8% in the fourth quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company’s stock valued at $17,949,296,000 after buying an additional 961,975 shares during the last quarter. Capital International Investors raised its stake in Amgen by 1.5% in the third quarter. Capital International Investors now owns 19,192,995 shares of the medical research company’s stock valued at $5,414,296,000 after buying an additional 282,219 shares during the last quarter. Capital World Investors raised its stake in Amgen by 11.5% in the third quarter. Capital World Investors now owns 18,795,474 shares of the medical research company’s stock valued at $5,303,578,000 after buying an additional 1,935,876 shares during the last quarter. Capital Research Global Investors raised its stake in Amgen by 2.7% in the third quarter. Capital Research Global Investors now owns 4,731,290 shares of the medical research company’s stock valued at $1,335,168,000 after buying an additional 122,631 shares during the last quarter. Finally, Invesco Ltd. raised its stake in Amgen by 6.6% in the third quarter. Invesco Ltd. now owns 4,467,287 shares of the medical research company’s stock valued at $1,260,668,000 after buying an additional 277,031 shares during the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. Oppenheimer set a $400.00 price target on Amgen and gave the company an “outperform” rating in a research note on Thursday, January 29th. Erste Group Bank reissued a “hold” rating on shares of Amgen in a report on Tuesday, May 5th. Rothschild & Co Redburn increased their price objective on Amgen from $180.00 to $200.00 and gave the company a “sell” rating in a report on Wednesday, February 18th. Truist Financial increased their price objective on Amgen from $325.00 to $327.00 and gave the company a “hold” rating in a report on Friday, May 1st. Finally, Daiwa Securities Group cut their price objective on Amgen from $410.00 to $390.00 and set an “outperform” rating on the stock in a report on Wednesday. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $356.15.

Insider Buying and Selling

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the firm’s stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the sale, the senior vice president directly owned 7,009 shares of the company’s stock, valued at $2,269,023.57. This trade represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.85% of the stock is currently owned by company insiders.

Amgen Stock Down 3.0%

Shares of AMGN stock opened at $326.31 on Friday. The stock’s 50-day simple moving average is $349.17 and its 200-day simple moving average is $342.99. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26. The firm has a market capitalization of $176.10 billion, a PE ratio of 22.71, a P/E/G ratio of 3.28 and a beta of 0.44. Amgen Inc. has a fifty-two week low of $267.73 and a fifty-two week high of $391.29.

Amgen (NASDAQ:AMGN) last posted its earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, topping the consensus estimate of $4.77 by $0.38. The firm had revenue of $8.62 billion for the quarter, compared to analyst estimates of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.Amgen’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same period last year, the company earned $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Equities analysts expect that Amgen Inc. will post 22.37 earnings per share for the current year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be issued a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a yield of 3.1%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s dividend payout ratio (DPR) is 70.15%.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.